Abstract
Behavioral activation (BA) therapy is an effective treatment for major depressive disorder (MDD) that targets anhedonia by enhancing opportunities for positive reinforcement. Anhedonic depression is also associated with alterations of the kynurenine pathway (KP), namely a decreased serum ratio of kynurenic acid (KynA) to quinolinic acid (QA). Whether this putative neuroprotective index is predictive of BA therapy outcomes or altered by BA therapy has not been evaluated.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call